within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AP07_Daclatasvir;

model Daclatasvir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.67,
    Cl = 4.138888888888889e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.047,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.01933333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.101,
    k12 = 2.311111111111111e-06,
    k21 = 2.311111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Daclatasvir</td></tr><tr><td>ATC code:</td><td>J05AP07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>47</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14.9</td><td>liter/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Daclatasvir is a direct-acting antiviral medication that acts as an inhibitor of the HCV NS5A protein, thereby inhibiting hepatitis C virus (HCV) replication. It is approved for use, often in combination with other antivirals, for the treatment of chronic HCV infection in adults.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult subjects (sex not specified) after single oral dose.</p><h4>References</h4><ol><li><p>Osawa, M, et al., &amp; Garimella, T (2019). Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. <i>Clinical pharmacology in drug development</i> 8(6) 802–817. DOI:<a href=\"https://doi.org/10.1002/cpdd.649\">10.1002/cpdd.649</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30629858/\">https://pubmed.ncbi.nlm.nih.gov/30629858</a></p></li><li><p>Al-Nahari, MM, et al., &amp; Farid, SF (2020). Pharmacokinetics of daclatasvir in Egyptian adolescents with genotype-4 HCV infection. <i>Antiviral therapy</i> 25(2) 101–110. DOI:<a href=\"https://doi.org/10.3851/IMP3357\">10.3851/IMP3357</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32367815/\">https://pubmed.ncbi.nlm.nih.gov/32367815</a></p></li><li><p>Osawa, M, et al., &amp; Garimella, T (2018). Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. <i>Journal of clinical pharmacology</i> 58(11) 1468–1478. DOI:<a href=\"https://doi.org/10.1002/jcph.1274\">10.1002/jcph.1274</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30063254/\">https://pubmed.ncbi.nlm.nih.gov/30063254</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AP07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Daclatasvir;
